Michael Soulen, MD

Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.

A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.

New research compares transarterial embolization and chemoembolization for treating neuroendocrine liver metastases, revealing unexpected safety differences.